Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $135.0833.

A number of research firms have commented on ABVX. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Citizens Jmp lifted their price objective on Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a research report on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, January 21st. Oppenheimer set a $131.00 price target on Abivax in a report on Thursday, January 8th. Finally, Morgan Stanley boosted their price target on shares of Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, January 9th.

Abivax Stock Up 1.4%

NASDAQ ABVX opened at $124.54 on Friday. The business has a fifty day moving average price of $122.66 and a 200 day moving average price of $101.56. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The company has a market cap of $9.77 billion, a P/E ratio of -29.79 and a beta of 0.79. Abivax has a one year low of $4.77 and a one year high of $148.83.

Abivax (NASDAQ:ABVX) last issued its earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million for the quarter. Research analysts anticipate that Abivax will post -2.83 EPS for the current fiscal year.

Institutional Trading of Abivax

Several hedge funds have recently made changes to their positions in ABVX. EverSource Wealth Advisors LLC increased its holdings in shares of Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after buying an additional 369 shares during the last quarter. First Horizon Corp purchased a new position in Abivax in the third quarter worth approximately $36,000. WPG Advisers LLC increased its stake in Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after acquiring an additional 253 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new position in shares of Abivax during the 4th quarter worth $67,000. Finally, Hantz Financial Services Inc. purchased a new stake in shares of Abivax in the 3rd quarter worth about $52,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.